Resources from the same session
LBA85 - TAR-200 +/- cetrelimab (CET) and CET alone in patients (pts) with bacillus Calmette-Guérin-unresponsive (BCG UR) high-risk non-muscle-invasive bladder cancer (HR NMIBC): Updated results from SunRISe-1 (SR-1)
Presenter: Michiel van der Heijden
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1964MO - Alliance A031501: AMBASSADOR study of adjuvant pembrolizumab (Pembro) in muscle-invasive urothelial carcinoma (MIUC) vs observation (Obs): Extended follow-up disease-free survival (DFS) results and metastatic (met) disease recurrence distribution
Presenter: Andrea Apolo
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1970MO - Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial
Presenter: Alexandra Drakaki
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA85, 1964MO and 1970MO
Presenter: Maria De Santis
Session: Mini oral session: GU tumours, non-prostate
Resources:
Slides
Webcast
LBA76 - Anlotinib in combined with anti-PD-L1 antibody Benmelstobart(TQB2450) versus sunitinib in first-line treatment of advanced renal cell carcinoma (RCC): A randomized, open-label, phase III study (ETER100)
Presenter: Xinan Sheng
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
LBA77 - Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial
Presenter: Chiara Ciccarese
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1694MO - Novel serum glycoproteomic biomarkers predict response to nivolumab plus cabozantinib (NIVO+CABO) versus sunitinib (SUN) in advanced RCC (aRCC): Analysis from CheckMate 9ER
Presenter: David Braun
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1965MO - Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
Presenter: Vadim Koshkin
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1966MO - EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
Presenter: Thomas Powles
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast
1967MO - Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
Presenter: Matthew Galsky
Session: Mini oral session: GU tumours, non-prostate
Resources:
Abstract
Slides
Webcast